According to the Zhitong Finance App, Okanvision Bio-B (01477) announced that the phase III clinical trial of OT-202 (spleen tyrosine kinase inhibitor/vascular endothelial growth factor receptor 2) for the treatment of dry eye syndrome (DED) in China has completed the enrollment of the first patient. The successful enrollment of the first patient marks an important milestone in the clinical development of OT-202 in China and reflects the Group's commitment to advancing innovative treatments for dry eye patients.
OT-202 (spleen tyrosine kinase inhibitor/vascular endothelial growth factor receptor 2) is the first novel drug of its kind developed by the company to treat moderate to severe dry eye. The mechanism of action of OT-202 is an inhibitor that acts as a dual target of spleen tyrosine kinase (Syk) and vascular endothelial growth factor receptor 2. It has a synergistic effect in treating dry eye and suppresses inflammatory response. In a phase I clinical trial successfully completed in February 2023, OT-202 showed good safety and tolerability in healthy adult subjects. The phase II clinical trial of OT-202 (started in February 2023 and is planned to be a randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and efficacy of the drug). A total of 213 patients were enrolled in the phase II clinical trial in China in November 2023. The results of the phase II clinical trial of OT-202 have been published in the top international ophthalmology journal “Ophthalmology”. In March 2024, the phase II clinical trial of OT-202 reached its main end.